| Document |
Document Title |
|
WO/2006/047167A2 |
9-Alkyl- and 9-alkylidenyl-6-O-alkyl-11,12-carbamate-ketolide and 9-alkylidene-6-O-alkyl-11,12-carbamate-ketolide antimicrobials of the Formula: wherein Ra, Rb, Rc R, L, T, Y, and Z are as described herein and in which the substituents h...
|
|
WO/2006/046112A2 |
The present invention provides ketolide derivatives, which can be used as anti-bacterial agents. Compounds disclosed herein can be used for the treating or preventing conditions caused by or contributed to by gram positive, gram negative...
|
|
WO/2006/042454A1 |
The present invention provides acetylated derivatives of the compound puerarin that have enhanced bioavailability and are particularly suitable for oral administration. The present invention also teaches the use of medicaments containing...
|
|
WO/2006/039263A2 |
The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) (II) which exhibit antibacterial properties. The present invention further relates to pharmaceutical c...
|
|
WO/2006/037159A1 |
A method of identifying biologically active compounds with defined selectivity profile comprises: (c) designing a library of compounds of formula (1) to scan molecular diversity; and (d) assaying the library of compounds in at least two ...
|
|
WO/2006/035301A2 |
The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed to by Gram-positive, Gram-negative or an...
|
|
WO/2006/033412A1 |
An alleviator for radiation disorders which is safe even when administered to the living body; and a composition containing the alleviator for radiation disorders. The alleviator for radiation disorders contains &agr -D-glucopyranosyl-(1...
|
|
WO/2006/025051A2 |
The present invention provides a process of preparing a crystalline azithromycin monohydrate. The process involves dissolving azithromycin in a solution containing ethanol, adding the dissolved azithromycin into water to precipitate the ...
|
|
WO/2006/024405A2 |
A compound of the formula (I) wherein the bond between carbon atoms 22 and 23 indicated with a broken line is a single or double bond, n is 0, 1 or 2, R1 represents, for instance, a C1-C12alkyl group, R2 represents, for instance, R15 gro...
|
|
WO/2006/022174A1 |
The invention aims at providing a method for inhibiting the browning and/or stinking of a composition and thus improving the storage stability of the composition. The aim is attained by a method which comprises adding a browning inhibito...
|
|
WO/2006/020712A1 |
A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.
|
|
WO/2006/017250A2 |
Sixteen membered macrolide anti-infective agents having a structure according to formula (I) where R1, R2, R3, R4, R5, and R6 are as defined herein, and related compounds are disclosed.
|
|
WO/2006/013409A1 |
The present invention provides acylide derivatives, which can be used as antibacterial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by Gram-positive, Gram-negat...
|
|
WO/2006/011561A1 |
Disclosed is a medicament for treating and/or preventing diabetes and the like which has excellent activity and safety. Specifically disclosed is a compound represented by the general formula (I) below or a pharmacologically acceptable s...
|
|
WO/2006/011160A1 |
The present invention relates to an improved, cost effective and easy process for the preparation of azithromycin monohydrate isopropanol clathrate. The process provides a one-step method of preparing azithromycin monohydrate isopropanol...
|
|
WO/2005/123711A1 |
The present invention relates to pharmaceutics and organic chemistry. The invention discloses a new kind of bicyclol glycosides and the preparation method thereof. The method comprises bicyclol being reacted with trichloroimide ester of ...
|
|
WO/2005/121161A1 |
The invention relates to substituted fluoroglycoside derivatives of pyrazoles of formula (I), in which the radicals have the indicated meanings, to the physiologically compatible salts thereof, and to a method for the production thereof....
|
|
WO/2005/121160A2 |
The present invention is directed to novel macrolide antibacterial agents and processes for preparing them. The present invention is further directed to pharmaceutical compositions containing the novel macrolide antibacterial agents disc...
|
|
WO/2005/118610A2 |
The present invention provides macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
|
|
WO/2005/112951A1 |
It is intended to provide an antitumor agent, which has established a strengthened function selectivity of acting exclusively on caner cells, lessened side effects, mastery of drug tolerance and so on, and has an activity of inducing cel...
|
|
WO/2005/111055A1 |
Kigamicins A, B, C, D and E represented by the following general formula (I) wherein R represents a sugar chain selected from among the sugar chain of the following formula: and other various sugar chains; are obtained as novel antibioti...
|
|
WO/2005/108414A1 |
The present invention provides novel crystalline forms of the macrolide antibiotic 9-(S)-erythromycylamine, and methods of preparing and using the same.
|
|
WO/2005/108413A1 |
The present invention relates to 14- or 15-membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis ...
|
|
WO/2005/108412A1 |
The present invention relates to 14- or 15-membered macrolides substituted at the 4” position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxi...
|
|
WO/2005/105821A2 |
The present invention relates to the process for the preparation of compounds of formula (I) or its pharmaceutically acceptable salts.The novel compounds (i) 10,11-Anhydro-2',4'-di-O-benzoyl-12-O-imidazolylcarbonyl-6-O
-methylerythromyci...
|
|
WO/2005/097106A1 |
Compositions of purified and biologically active ellagitannins, including punicalagin, are provided by separation from pomengranate husk using a method of extraction and purification using a solid polymeric adsorbent.
|
|
WO/2005/090377A1 |
The present invention relates to a process for the production of clarithromycin using solvents with a low toxic potential and water.
|
|
WO/2005/087787A1 |
The 2-fluoro-6-O-substituted ketolide derivative represented by the formula [Chemical formula 1] (1) or a pharmaceutically acceptable salt or hydrate thereof. They are new erythromycin derivatives which have potent antibacterial activity...
|
|
WO/2005/087786A1 |
The invention relates to: (i) the use of osyl derivatives of genkwanin and sakuranetin having formula (I) in (a) cosmetics or dermatology and (b) therapeutics; (ii) the use of novel derivatives having formula (I) as industrial products; ...
|
|
WO/2005/085266A2 |
The present invention provides macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.
|
|
WO/2005/084689A1 |
The invention discloses a Radix astragli extract and production method and use thereof. Such Radix astragli extract mainly comprises astragalus saponin, organic acid and astragalus flavonoid glycoside. Such production method consists of ...
|
|
WO/2005/085223A1 |
A medicine, functional food, or health food which are effective in the prevention and/or treatment of bone diseases, and contain as an active ingredient a safe flavonoid compound derived from a natural material. Also provided is a medici...
|
|
WO/2005/085267A1 |
Nitrogenous fused-ring derivatives represented by the general formula (I) which exert human SGLT inhibiting activity and are useful as preventive or therapeutic agents for diseases caused by hyperglycemia, for example, diabetes, postpran...
|
|
WO/2005/085265A1 |
A nitrogenous fused-ring derivative represented by the following general formula (I), a pharmacologically acceptable salt thereof, or a prodrug of either. They have human SGLT inhibitory activity and are useful as a preventive or therape...
|
|
WO/2005/081821A2 |
The present invention includes EP-13420 polymorphic crystalline forms: Form I, Form II, Form Ia, and monohydrate and amorphous EP-13420 which posses distinct physical properties. In another embodiment of the present invention, there are ...
|
|
WO/2005/080408A1 |
The present invention provides a method for preparing bridged macrocyclic compounds comprising the step of reacting a macrocyclic compound characterized by having at least two nucleophilic moieties with a bifunctional bridging reagent op...
|
|
WO/2005/080549A2 |
The invention relates to the use of trioxacarcins as agents for treating infections caused by fungi, parasites, viruses or bacteria. The invention also relates to the novel trioxacarcin derivatives as such, to drugs containing them or th...
|
|
WO/2005/075494A1 |
Macrolide compounds of formula (I) wherein X, R, R1, R2, R3 and R4 have the meanings as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and the use...
|
|
WO/2005/075495A1 |
6-O-Substituted ketolide derivatives represented by the following general formula: [Chemical formula 1] wherein R represents hydrogen atom or a fluorine atom; or pharmaceutically acceptable salts thereof have potent antibacterial effects...
|
|
WO/2005/072762A1 |
Provided are processes for the preparation of compositions enriched in phenolic compounds from a crude plant extract. One process includes a novel column purification step using a polymer resin that releasably absorbs the phenolic compou...
|
|
WO/2005/072204A2 |
Compounds of Formula (I), and pharmaceutically acceptable salts, esters, and prodrugs thereof: (I) are disclosed, wherein A, B, D, L, X, Y, Z and R2' are described herein. The compounds exhibit antibacterial properties. The compounds of ...
|
|
WO/2005/070918A1 |
The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivatives. In particular, the presen tinvention relates to processes and intermediates for the preparation of a compound of ...
|
|
WO/2005/070427A1 |
The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative ther...
|
|
WO/2005/070113A2 |
The present invention discloses compounds of formula (I), (II), (III), or (IV), or a racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: formulas (I), (II), (III), (IV), which exhibit antibacterial properties. The present ...
|
|
WO/2005/068485A1 |
The present invention relates to the pharmaceutical composition and health care food comprising flavonoid compounds isolated from the extract of Sedum sarmentosum Bunge for preventing and treating hypertension. The flavonoid compounds of...
|
|
WO/2005/067919A1 |
The present invention discloses compounds of formulae I, II, III or IV or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I), (II), (III), (IV), which exhibit antibacterial properties. The present invention further relat...
|
|
WO/2005/067564A2 |
The present invention discloses compounds of formulaes I, II, III, or IV, or a 5 racemate, enantiomer, regioisomer, salt, ester or prodrug thereof: which exhibit antibacterial properties. The present invention further relates to pharmace...
|
|
WO/2005/068484A1 |
The invention relates to complexes of specific flavonoid derivatives of formula (I), to preparations containing derivatives of this type, to corresponding methods for producting the flavonoid derivatives or preparations containing the la...
|
|
WO/2005/063263A1 |
The invention relates to novel derivatives of morphine-6-glucuronide, the preparation method thereof and the uses of same in therapy, for example, as analgesics.
|
|
WO/2005/061526A1 |
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formule (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compos...
|
